6 terminated, 2 completed, 1 withdrawn. 5 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Completed 1, Withdrawn 1 |
| Phase 2 | 4 | Terminated 4 |
| Phase 3 | 1 | Completed 1 |
Follow NIS-793: new trials by email Literature Review of NIS-793 trials Research Report on NIS-793
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Terminated | Kimberly Perez, MD | 8 | 2023-01-06 | 2024-12-17 |
| FOLFIRINOX + NIS793 in Pancreatic Cancer FOLFIRINOX, Oxaliplatin, Leucovorin - Pancreas Cancer, Metastatic Pancreatic Cancer | Phase 1 | Terminated | Colin D. Weekes, M.D., PhD | 4 | 2022-08-09 | 2025-11-18 |
| Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC NIS793, Bevacizumab, Modified FOLFOX6 - Metastatic Colorectal Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 202 | 2021-11-15 | 2026-11-16 |
| Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 NIS793, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Completed | Novartis Pharmaceuticals | 511 | 2021-09-30 | 2026-05-19 |
| Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS MBG453, NIS793, canakinumab - Myelodysplastic Syndromes | Phase 1 | Terminated | Novartis Pharmaceuticals | 33 | 2021-06-18 | 2025-10-10 |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) NIS793, Spartalizumab, gemcitabine - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Novartis Pharmaceuticals | 164 | 2020-10-16 | 2025-10-16 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 45 | 2019-09-26 | 2025-08-07 |
| Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. NIS793, PDR001 - Breast Cancer, Lung Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 120 | 2017-04-25 | 2022-01-31 |
Pancreatic Neoplasms (3) · Colorectal Neoplasms (2) · Primary Myelofibrosis (2) · Breast Neoplasms (1) · Kidney Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Thrombocythemia, Essential (1)
Novartis Pharmaceuticals (7) · Colin D. Weekes, M.D., PhD (1) · Kimberly Perez, MD (1)
United States (7) · Italy (6) · Australia (5) · Germany (5) · Spain (5) · Switzerland (5) · Canada (4) · Singapore (4) · Taiwan (4) · United Kingdom (4) · Belgium (3) · Czechia (3) · France (3) · Israel (3) · Japan (3)
Colin D Weekes, MD, PHD (1) · Kimberly Perez, MD (1)
PMID 30832732, PMID 38030303, PMID 40334082
2019 (3), 2016 (1)